Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.47)
# 919
Out of 5,056 analysts
226
Total ratings
46.01%
Success rate
20.55%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $5.39 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $23.80 | +17.65% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $180.52 | -16.91% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $147.48 | +3.74% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $13.75 | +1.82% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $57.73 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.45 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $28.92 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $33.99 | +70.64% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.26 | +46.96% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $66.16 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.36 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $138.63 | +11.81% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.27 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $17.48 | +100.23% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.35 | +142.99% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.02 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.52 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.41 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.93 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $22.66 | +50.04% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $43.01 | +16.25% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $4.47 | +11.86% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.40 | +888.14% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.05 | +280.95% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $40.61 | +42.82% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.43 | +76,823.08% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $8.56 | +834.58% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.03 | +191.26% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $3.50 | +214.29% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.75 | +37.14% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.57 | +2,457.08% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.49 | +703.21% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $30.11 | +564.23% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.32 | +203.03% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.79 | +760.22% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.89 | +7,519.05% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.11 | +260.36% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $70.10 | -44.37% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $75.11 | -80.03% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.42 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.65 | +3,770.97% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.39
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $23.80
Upside: +17.65%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $180.52
Upside: -16.91%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $147.48
Upside: +3.74%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $13.75
Upside: +1.82%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $57.73
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.45
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.92
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $33.99
Upside: +70.64%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.26
Upside: +46.96%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.16
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.36
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $138.63
Upside: +11.81%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $17.48
Upside: +100.23%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.35
Upside: +142.99%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.02
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.52
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.41
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.93
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $22.66
Upside: +50.04%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $43.01
Upside: +16.25%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $4.47
Upside: +11.86%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.40
Upside: +888.14%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.05
Upside: +280.95%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $40.61
Upside: +42.82%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.43
Upside: +76,823.08%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $8.56
Upside: +834.58%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.03
Upside: +191.26%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $3.50
Upside: +214.29%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.75
Upside: +37.14%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.57
Upside: +2,457.08%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.49
Upside: +703.21%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $30.11
Upside: +564.23%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.32
Upside: +203.03%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.79
Upside: +760.22%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.89
Upside: +7,519.05%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.11
Upside: +260.36%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $70.10
Upside: -44.37%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $75.11
Upside: -80.03%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.42
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.65
Upside: +3,770.97%